Compounds > 4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide
Page last updated: 2024-11-13

4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,6-dichloro-N-(4,4-dimethylcyclohexyl)-1H-indole-2-carboxamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72694224
CHEMBL ID3086114
SCHEMBL ID15506666
MeSH IDM0592439

Synonyms (10)

Synonym
4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide
CHEMBL3086114
SCHEMBL15506666
AKOS027337119
1473450-60-0
nitd-304
CS-0056772
mfcd28502067
SB16950
P14963
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1054039Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse model assessed as log CFU reduction at 25 mg/kg, po qd administered for 28 days relative to untreated control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054050Aqueous solubility of the compound at pH 6.8 after 24 hrs by high-throughput equilibrium solubility assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1236431Volume of distribution in mouse2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
AID1054041Elimination half life in mouse at 25 mg/kg, po by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1635744AUClast in BALB/c mouse plasma at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635764Oral bioavailability in BALB/c mouse at 100 mg/kg administered as single dose for 30 to 120 mins followed by Mycobacterium tuberculosis H37Rv addition to compound treated serum incubated for 7 days by alamar blue reagent based serum inhibition titration a2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1054044Elimination half life in mouse at 5 mg/kg, iv by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1236433Oral bioavailability in mouse2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
AID1236430Systemic clearance in mouse2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
AID1635751Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse model assessed as reduction in CFU counts in lung at 100 mg/kg administered daily via oral gavage for 5 days per week measured after 14 days post dosage relative 2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1874383Cytotoxicity against African green monkey vero cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
AID1054040Oral bioavailability in mouse at 25 mg/kg by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054033Elimination half life in mouse at 5 mg/kg, iv and 75 mg/kg, po by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054049Intrinsic clearance in human liver microsomes by LC/MS/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1635747AUMClast in BALB/c mouse lung at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1054035Cytotoxicity against human THP1 cells2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054048Intrinsic clearance in mouse liver microsomes by LC/MS/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054042Cmax in mouse at 25 mg/kg, po by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054047Intrinsic clearance in rat liver microsomes by LC/MS/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054046Volume of distribution at steady state in mouse at 5 mg/kg, iv by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1883681Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID1635763Antimycobacterial activity against Mycobacterium tuberculosis H37Rv grown on serum of 100 mg/kg, po treated BALB/c mouse for 30 to 120 mins assessed as reduction in bacterial growth followed by bacterial addition incubated for 7 days by alamar blue reagen2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635740Tmax in BALB/c mouse plasma at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635754Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse model assessed as protection against mouse mortality at 12.5 to 100 mg/kg administered daily via oral gavage for 5 days per week measured after 14 to 28 days post2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635746AUMClast in BALB/c mouse plasma at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1054038Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in Balb/c mouse model assessed as log CFU reduction at 75 mg/kg, po qd administered for 28 days relative to untreated control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1054034AUC (0 to 24 hrs) in mouse at 5 mg/kg, iv and 75 mg/kg, po by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1635753Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse model assessed as reduction in CFU counts in lung at 200 mg/kg administered daily via oral gavage for 5 days per week measured after 28 days post dosage relative 2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1054045Clearance in mouse at 5 mg/kg, iv by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1635745AUClast in BALB/c mouse lung at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635741Tmax in BALB/c mouse lung at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1874384Selectivity index, ratio of IC50 for African green monkey vero cells to MIC for Mycobacterium tuberculosis H37Rv
AID1054043AUC (0 to 24 hrs) in mouse at 25 mg/kg, po by LC/MS analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
AID1635743Cmax in BALB/c mouse lung at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635749Mean residence time (last) in BALB/c mouse lung at 100 mg/kg administered via oral gavage by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1883719Antibacterial activity against Mycobacterium tuberculosis H37Rv in acute Mtb infection BALB/c mouse model assessed as reduction in log10 CFU in lungs at 100 mg/kg, po daily via gavage for 4 weeks2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID1236427Antimycobacterial activity against Mycobacterium tuberculosis assessed as inhibition of bacterial growth measured in glycerol-containing medium2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
AID1635748Mean residence time (last) in BALB/c mouse plasma at 100 mg/kg administered via oral gavage by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635742Cmax in BALB/c mouse plasma at 100 mg/kg administered via oral gavage after 0.25 to 24 hrs by LC-MS analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1635752Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse model assessed as reduction in CFU counts in lung at 100 mg/kg administered daily via oral gavage for 5 days per week measured after 28 days post dosage relative 2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
AID1874382Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 7 days by microplate alamar blue assay
AID1236432Elimination half life in mouse2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
AID1054051Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by three-fold serial dilution assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		2.1310ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
clofazimine
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.		3.5110monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		3.9430carbohydrazideantitubercular agent;
drug allergen
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		3.5110chromones
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.51104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
2-anthramine
2-anthramine: structure		2.1310anthracenamine
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.0810ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
fropenem
[no description available]		3.5110faropenem
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		3.5110carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
5-nitro-1,10-phenanthroline
5-nitro-1,10-phenanthroline: structure in first source		3.5110
nu 6027
[no description available]		3.5110
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		3.5110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
linezolid
[no description available]		3.5110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
u 100480
U 100480: structure given in first source		3.5110
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		3.5110pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.5110
bedaquiline
bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.		3.5110aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde o-(3,4-dichlorobenzyl)oxime
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime: a constitutive androstane receptor agonist; structure in first source		2.1310
btz 043
[no description available]		3.5110
pbtz169
macozinone: an antitubercular agent; structure in first source		3.5110
ceritinib
ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.		3.5110aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.1310cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		04.4440
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		04.4440
Tuberculosis, Drug-Resistant
[description not available]		02.1310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1310
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.1310